<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161380</url>
  </required_header>
  <id_info>
    <org_study_id>20140248</org_study_id>
    <secondary_id>1U10EY023558-01A1</secondary_id>
    <nct_id>NCT02161380</nct_id>
  </id_info>
  <brief_title>Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy</brief_title>
  <acronym>LHON</acronym>
  <official_title>An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Guy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypotheses:

      The primary hypothesis being tested is that there will be no toxicity resulting in loss of
      vision to no light perception in injected eyes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Primary Endpoint - Toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of local and general adverse events and Serious Adverse Events</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Leber's Hereditary Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>1(Chronic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of scAAV2-P1ND4v2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2(Acute)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of scAAV2-P1ND4v2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3(Presymptomatic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of scAAV2-P1ND4v2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injection of scAAV2-P1ND4v2 5.00x10e9 vg (Low),</intervention_name>
    <description>injection of Total Volume of each intravitreal injection is 200 µL</description>
    <arm_group_label>1(Chronic)</arm_group_label>
    <arm_group_label>2(Acute)</arm_group_label>
    <arm_group_label>3(Presymptomatic)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injection of scAAV2-P1ND4v2 2.46X10e10 vg (Med)</intervention_name>
    <description>injection of Total Volume of each intravitreal injection is 200 µL</description>
    <arm_group_label>1(Chronic)</arm_group_label>
    <arm_group_label>2(Acute)</arm_group_label>
    <arm_group_label>3(Presymptomatic)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injection of scAAV2-P1ND4v2 1.0X10e11vg (High)</intervention_name>
    <description>injection of Total Volume of each intravitreal injection is 200 µL</description>
    <arm_group_label>1(Chronic)</arm_group_label>
    <arm_group_label>2(Acute)</arm_group_label>
    <arm_group_label>3(Presymptomatic)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 15 or older;

          2. Patients with LHON and the G11778A mitochondrial DNA mutation. A previous CLIA
             certified genetic lab result showing the LHON G11778A mutation will be accepted for
             inclusion;

          3. Ability to perform tests of visual and retinal function;

          4. Ability to comply with research procedures;

          5. Able and willing to provide informed consent before undergoing any study related
             procedures.

          6. Good general health as based on the investigator's assessment of the history, physical
             examination and laboratory testing performed at the baseline examination.

        Exclusion Criteria:

          1. Unwilling or unable to give consent,

          2. Unable or unlikely to return for scheduled protocol visits

          3. Pregnant or nursing women or unwillingness for subject with childbearing potential to
             use contraception during the first year of the study.

          4. Optic disc drusen on exam or in previous history.

          5. Ocular diseases or visual dysfunction conditions other than refractive error (e.g.
             amblyopia, glaucoma, etc.) in the eye selected for the injection.

          6. Previous eye surgery in the eye selected for injection.

          7. Aspartate transaminase (AST)/alanine transaminase (ALT) &gt;5.0 x upper limit of normal
             (ULN); Total bilirubin &gt;3 x ULN; Hemoglobin &lt; 8 g/dL; neutrophil count &lt;1.0 x 109/L;
             or platelet count &lt; 50 x 109/L

             a) Any laboratory screening test that meets the abnormality criteria stated above can
             be repeated once between Baseline one to Baseline 2.

          8. Type I diabetes or the presence of diabetic retinopathy

          9. History of neurodegenerative conditions (e.g. multiple sclerosis, neuromyelitis
             optica, Parkinson disease)

         10. History of autoimmune conditions (e.g. systemic lupus erythematosus)

         11. History of systemic diseases having ocular manifestations likely to confound
             assessment of study results.

         12. History of cancer within five years other than localized basal or squamous cell
             carcinoma not near the orbital area. Patients with a prior history of cancer will need
             documentation from their cancer specialist that the cancer was cured at least 5 years
             before study entry.

         13. Allergy to pupil dilating drops or narrow angles precluding safe dilation.

         14. No Light Perception (NLP) vision in either eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JOHN GUY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL 33136</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JOHN GUY, MD</last_name>
    <phone>302-326-6036</phone>
    <email>jguy@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JOHN GUY, MD</last_name>
      <phone>305-326-6036</phone>
      <email>jguy@miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Phillip Gonzalez, CCRP</last_name>
      <phone>305-482-4739</phone>
      <email>jpgonzalez@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>JOHN GUY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://bascompalmer.org/news</url>
    <description>Bascom Palmer News</description>
  </link>
  <results_reference>
    <citation>Feuer WJ, Schiffman JC, Davis JL, Porciatti V, Gonzalez P, Koilkonda RD, Yuan H, Lalwani A, Lam BL, Guy J. Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results. Ophthalmology. 2016 Mar;123(3):558-70. doi: 10.1016/j.ophtha.2015.10.025. Epub 2015 Nov 19.</citation>
    <PMID>26606867</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2014</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>John Guy</investigator_full_name>
    <investigator_title>Professor of Neuro-ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Gene therapy</keyword>
  <keyword>Mitochondrial Genes</keyword>
  <keyword>Leber's</keyword>
  <keyword>AAV2 Viral vectors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Atrophy, Hereditary, Leber</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

